Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Oral P2Y12 Inhibitors and Drug Interactions
Author(s): Elisabetta Bigagli , Jacopo Angelini , Alessandro Mugelli , et al Added: 11 months ago

Anticoagulation

Prevention & Chronic Conditions
SGLT2 Inhibitors in Acute Heart Failure
Author(s): Hugo Prado-Prado , Sergio Raposeiras-Roubín Added: 2 months ago

Heart Failure
Factor XIa Inhibitors’ Future Position in AF
Author(s): Maki Komiyama , Moritake Iguchi , Hiromichi Wada , et al Added: 1 year ago

Anticoagulation
30th Annual Meeting of the ISCP
Author(s): Alberto Alen Andrés , María Salgado , Maria Fernández García , et al Added: 1 month ago

Prevention & Chronic Conditions

Heart Failure
AHA 25: The CORALreef HeFH Trial
Author(s): Christie Ballantyne Added: 6 months ago
AHA Scientific Sessions 2025 - Dr Christie Ballantyne (Baylor College of Medicine, Houston, TX, US) discusses findings from the CORALreef HeFH trial, examining the efficacy and safety of enlicitide decanoate, an oral PCSK9 inhibitor, in adults with heterozygous familial hypercholesterolemia.This Phase 3, randomized, double-blind, placebo-controlled study evaluated 303 participants with… View more

Cardiovascular Kidney Metabolic
Enlicitide: Oral PCSK9 Inhibitor Lowers LDL-C by 56%
Added: 2 months ago Source:  Radcliffe Cardiology
Written by Mirjam Boros, Radcliffe CardiologyA new oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, enlicitide, has demonstrated a significant reduction in low-density lipoprotein cholesterol (LDL-C) levels in patients with or at risk of atherosclerotic cardiovascular disease (ASCVD), according to results from the CORALreef Lipids trial.¹Mechanism of ActionEnlicitide is an… View more

Cardiovascular Kidney Metabolic

Prevention & Chronic Conditions
Author(s): Byoung Geol Choi , Seung-Woon Rha , Se Yeon Choi , et al Added: 1 year ago

Anticoagulation
Sex Influences DAPT De-escalation Outcomes Post-PCI
Added: 3 weeks ago Source:  Interventional Cardiology
De-escalation of dual antiplatelet therapy (DAPT) is a strategy used to improve outcomes after percutaneous coronary intervention (PCI).¹˒² However, the impact of patient sex on the safety and efficacy of these strategies has been unclear. A new network meta-analysis published in the European Heart Journal has investigated these potential differences.¹MethodologyThe study analysed data from 20… View more

Intervention

Anticoagulation
Ticagrelor Fails Noninferiority to Prasugrel in TUXEDO-2
Added: 2 months ago Source:  Radcliffe CVRM
Written by Mirjam Boros, Radcliffe CardiologyThe optimal dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) in high-risk patients with diabetes and multivessel disease remains a key clinical question. The TUXEDO-2 trial aimed to address this by directly comparing the efficacy and safety of ticagrelor versus prasugrel in this specific patient population… View more

Anticoagulation

Cardiovascular Kidney Metabolic
30th Annual Meeting of the ISCP
Author(s): Raúl Ludeña , Raúl Ptaszynski Lanza , Beatriz Nieves Ureña , et al Added: 1 month ago

Prevention & Chronic Conditions